|Articles|March 1, 2002

March 2002
Volume 8
Issue 3

Use of Alternative Pharmacotherapy in Management of Cardiovascular Diseases

Author(s)Larisa Chagan, PharmD, Anna Ioselovich, PharmD, Liya Asherova, PharmD

Download PDF: Use of Alternative Pharmacotherapy in Management of Cardiovascular Diseases

Articles in this issue

over 24 years ago

Article

Application of Cost-Effectiveness Analysis to Multiple Products: A Practical Guide

over 24 years ago

Article

Diagnostic Testing or Empirical Neuraminidase Inhibitor Therapy for Patients with Influenza-Like Illness: What a Difference a Day Makes

over 24 years ago

Article

over 24 years ago

Article

over 24 years ago

Article

Development and Maintenance of a Community-Based Hepatitis C Registry

over 24 years ago

Article

Value for Money in Health and Medical Care Services

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Health Care Utilization in Veterans With Alzheimer Disease

ByYing Wang, PhD,Byron J. Aguilar, PhD,Mingfei Li, PhD,Peter Morin, MD, PhD,Joel Reisman, BS,Wen Hu, MS,Jong Soo Lee, PhD,Dan Berlowitz, MD, MPH,Qinqing Li, MS,Raymond Zhang, PhD,Amir Abbas Tahami Monfared, MD, PhD,Quanwu Zhang, PhD,Weiming Xia, PhD

June 4th 2026

Health care costs | Image Credit: © Valeri Luzina - stock.adobe.com

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

ByPooja Chandrashekar, MD, MBA,Sachin H. Jain, MD, MBA

June 4th 2026

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

ByAllison Spitery, PharmD, BCACP,Alison Lobkovich, PharmD, BCACP,Emily Thomas, PharmD, BCPS, BCACP

June 4th 2026

Use of Alternative Pharmacotherapy in Management of Cardiovascular Diseases

Articles in this issue

Related Content

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Health Care Utilization in Veterans With Alzheimer Disease

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

Trending on AJMC

Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss

GLP-1 Drugs Tackle Both Skin Inflammation and Metabolism in Psoriasis

Measles Cases Climb to 2000 in the US, Increasing Cases Year Over Year

Childhood Influenza Vaccine Rates Decreased From 2017 to 2023

Oral Orforglipron Added to Basal Insulin Cuts HbA1c in Type 2 Diabetes